Shares of Allarity Therapeutics, Inc. (ALLR) are surging more than 125% Tuesday morning at $2.69.
Monday, the company said it initiated the Phase 1b study of the combination therapy of its drug candidates stenoparib and dovitinib to treat advanced solid tumors, including ovarian cancer.
Interim data readouts from the ongoing Phase 2 monotherapy studies of Dovinitinb and Stenoparib are expected in late 2023.
ALLR has traded in the range of $1.04- $118.30 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.